Dr. Mechoulam’s latest discovery is called EPM301, or cannabidiolic acid methyl ester, also known as CBDa. EPM stands for Endless Potential Molecules, and there are now around 14 patented molecules that are being tested on humans with the US FDAs guidance. The first targets of EPM are psoriasis and inflammatory bowel disease (IBD), which are notoriously difficult to treat.